英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Adcentrx Therapeutics
    Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases
  • Pipeline - Adcentrx Therapeutics
    Adcentrx is building an internal pipeline of novel ADCs
  • About - Adcentrx Therapeutics
    At Adcentrx, we are driven to create the best therapies to treat serious and life-threatening diseases By leveraging a deep understanding of chemistry and biology, our goal is to purposefully solve the issues faced by ADCs in the past and develop improved protein conjugate therapies for patients with the highest unmet needs
  • News - Adcentrx Therapeutics
    Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors October 21, 2024
  • Management Team - Adcentrx Therapeutics
    Adcentrx Therapeutics has built a team with deep expertise in ADC development
  • Our Science - Adcentrx Therapeutics
    At Adcentrx, we look beyond a one-size-fits-all platform approach to developing protein conjugates, such as ADCs Our goal is to develop first-in-class and best-in-class therapies that broaden the therapeutic window in treating cancer and other life-threatening diseases
  • Adcentrx Therapeutics Announces FDA Clearance of Investigational New . . .
    Second asset utilizing Adcentrx’s ADC platform to receive IND clearance Dosing of first patient in a Phase 1a b clinical trial anticipated by 4Q 2024 SAN DIEGO, CA, October 21, 2024 PR NEWSWIRE — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening diseases, today announced that the U
  • Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a b . . .
    SAN DIEGO, CA, January 6, 2025 PR NEWSWIRE — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening diseases, today announced the first patient dosed in the Phase 1a b study of ADRX-0405 for the treatment of advanced solid tumors


















中文字典-英文字典  2005-2009